Market Is Estimated To Witness High Growth Owing To Rising Demand And Technological Advancements
The Non-PVC IV bags market is estimated to be valued at USD 2.20 Bn in 2024 and is expected to exhibit CAGR of 10.5% over the forecast period 2024-2031. The market is witnessing high growth owing to rising demand for non-toxic and environment-friendly IV bags from the healthcare sector and advancements in materials used for manufacturing non-PVC IV bags. Furthermore, increasing preference for single-use and ready-to-use IV bags is also fueling market growth.
Market Dynamics:
Increasing demand and rising healthcare expenditure: Growing prevalence of chronic diseases is increasing hospital admissions and surgical procedures. This is fueling the demand for intravenous therapy and IV fluid administration. Additionally, rising healthcare expenditure in developing nations is also driving market growth. Advancements in material technology: Manufacturers are increasingly focusing on developing novel materials to manufacture IV bags that are non-toxic and environment-friendly. Recently developed materials like multilayer co-extruded films provide effective barrier against fluids. Continuous innovations are further supporting market expansion. The global non-PVC IV bags market is driven by rising demand for IV therapy owed to growing disease burden and increasing preference for single-use and environment-friendly IV bags from the healthcare sector. Technological advancements are also supporting market growth through development of novel materials.
Increasing Demand for Safer and Non-Toxic Medical Products is Driving the Adoption of Non-PVC IV Bags
The growing awareness about the harmful effects of PVC on human health and the environment is a major factor driving the demand for non-PVC IV bags. PVC contains chlorine which produces dioxin as a byproduct during manufacturing and disposal processes. Dioxins are highly toxic and are known to cause cancer and reproductive and developmental problems. With increasing research highlighting the dangers of medical PVC, hospitals and healthcare institutions are looking for safer alternatives. Non-PVC materials like copolyesters and ethyl vinyl acetate are free from chlorine and dioxins, making them a more sustainable option for long-term patient care.
Growing Preference for Single-Use Disposable Medical Products is Fueling Market Growth
The shift from reusable to single-use disposable medical products is another key driver for non-PVC IV bags. Single-use plastics eliminate the risk of cross-contamination between patients by medical equipment and help improve sterility. With growing hygiene standards and safety regulations, single-use non-PVC IV bags are fast becoming the norm in developed markets. The convenient and cost-effective nature of disposable bags also encourages greater adoption rates. This trend is expected to continue and support non-PVC IV bag demand, especially in developing countries with improving healthcare infrastructures.
High Production Costs of Non-PVC Materials Pose a Challenge
One of the major restraints faced by non-PVC IV bag manufacturers is the higher production cost of alternative materials compared to PVC. Specialty polymers like copolyesters require complex production processes that drive up capital expenditure and operating costs. This makes non-PVC bags more expensive than conventional PVC variants. As healthcare budgets remain tight in most countries, the premium pricing of eco-friendly bags puts pressure on margins. Convincing hospitals and patients to bear the incremental cost is also a challenge. Unless production technologies advance to bring down costs substantially, price sensitivity will continue to hamper non-PVC IV bag market expansion.
Lack of Global Regulatory Pushbacks Slows Adoption Rates
Unlike Europe which has introduced a complete ban on medical PVC, regulatory policies in other parts of the world lack a cohesive strategy restricting the use of PVC in healthcare. While concerns over phthalate plasticizers are growing, enforcement of substitution varies greatly between regions. The absence of a globally synchronized regulatory framework discouraging PVC continues to support the demand for cheaper alternatives. Stronger environmental laws and clinical waste management protocols need to be established worldwide to stimulate faster conversion to non-toxic materials like non-PVC bags. Until regulatory risks incentivize the transition, adoption rates may remain slower than expected.
Growing Emphasis on Safer Healthcare Products Present Opportunities
With patient safety and environmental protection gaining prominence worldwide, manufacturers have an opportunity to leverage the growing emphasis on safer medical product design and materials. Educating hospitals, practitioners as well as the general public about the health dangers of PVC use can boost acceptability of non-PVC alternatives. Presenting clinical evidence on product performance along with lifecycle analysis highlighting environmental benefits can convince customers on remaining competitive while being eco-friendly. Leveraging sustainable procurement policies and green certification programs is another avenue to promote non-PVC bags.
Investments in manufacturing Process Innovations Can Help Lower Costs
Continued investments into material science and production process R&D provides opportunities for lowering the manufacturing costs of non-PVC bags. Technologies optimizing reactor designs, energy efficiency and waste reduction can significantly enhance the economics of specialty polymers. Collaboration with material vendors, equipment suppliers as well as research institutions focused on new polymer formulations, advanced film casting and integrated manufacturing will be pivotal. With costs narrowed down, non-PVC bags can achieve wider price-point accessibility and market penetration over the long-term.
Link: https://www.coherentmarketinsights.com/market-insight/non-pvc-iv-bags-market-4840
Key Development
- On 22 February 2024, Xheme, Inc., a specialty materials company focused on eco-friendly multifunctional technologies targeting oxidative stress reduction, is collaborating with Vitalant Research Institute, a prominent transfusion medicine research entity, to develop a non-toxic, non-PVC film technology. This innovation aims to preserve limited blood supplies and comply with forthcoming European Union regulations for medical plastics.
- In June 2022, Gufic Biosciences, pharmaceutical company unveiled premium Dual Chamber bags crafted from polypropylene (DEHP-free) with a peelable aluminum foil, enabling the storage of unstable drugs requiring reconstitution before patient administration.
- In April 2022, Fresenius Kabi, global healthcare company introduced Calcium Gluconate in Sodium Chloride Injection in ready-to-administer freeflex bags in the United States. These freeflex packs are constructed from polyolefin, eliminating Di-ethylhexyl-phthalate (DEHP) plasticizers and PVC.
- In August 2020, ICU Medical, Inc. medical devices company has announced a long-term partnership with Grifols global healthcare company to distribute a comprehensive range of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP in the United States. This collaboration extends ICU Medical's non-PVC/non-DEHP product line to encompass container sizes ranging from 50 mL to 1000 mL. Additionally, ICU Medical intends to distribute Grifols' Dextrose IV solutions pending regulatory approval for sale in the United States.
Key Players:
Baxter International Inc., B. Braun Melsungen AG, Pfizer Inc. (Hospira), Fresenius Kabi AG, KRATON CORPORATION, PolyCine GmbH, Renolit, Technoflex, Otsuka Pharmaceutical India Private Limited, Sippex IV bag, Shanghai Solve Care Co., Ltd., Jiangxi Sanxin Medtec Co., Ltd., Angiplast Private Limited, Shanghai Kindly Enterprise Development Group Co., Ltd., Qingdao Huaren Medical Product Co., Ltd., Beijing Double-Crane Pharmaceutical Equipment Co., Ltd., Huizhou Foryou Medical Devices Co., Ltd., Parekhplast India Limited, and Nipro.
